<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30306429</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>03</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1573-7217</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>10</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research and treatment</Title>                <ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>            </Journal>            <ArticleTitle>The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-018-4988-3</ELocationID>            <Abstract>                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Little is known about whether gene expression profile (GEP) testing and specific recurrence scores (e.g., medium risk) improve women's confidence in their chemotherapy decision or perceived recurrence risk. We evaluate the relationship between these outcomes and GEP testing.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We surveyed women eligible for GEP testing (stage I or II, Gr1-2, ER+, HER2-) identified through the Surveillance, Epidemiology, and End Results (SEER) Registry of Washington or Kaiser Permanente Northern California from 2012 to 2016, approximately 0-4 years from diagnosis (N = 904, RR = 45.4%). Confidence in chemotherapy was measured as confident (Very, completely) versus Not Confident (Somewhat, A little, Not At All); perceived risk recurrence was recorded numerically (0-100%). Women reported their GEP test receipt (Yes, No, Unknown) and risk recurrence score (High, Intermediate, Low, Unknown). In our analytic sample (N = 833), we propensity score weighted the three test receipt cohorts and used propensity weighted multivariable regressions to examine associations between the outcomes and the three test receipt cohorts, with receipt stratified by score.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">29.5% reported an unknown GEP test receipt; 86% being confident. Compared to no test receipt, an intermediate score (aOR 0.34; 95% CI 0.20-0.58), unknown score (aOR 0.09; 95% CI 0.05-0.18), and unknown test receipt (aOR 0.37; 95% CI 0.24-0.57) were less likely to report confidence. Most women greatly overestimated their recurrence risk regardless of their test receipt or score.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GEP testing was not associated with greater confidence in chemotherapy decisions. Better communication about GEP testing and the implications for recurrence risk may improve women's decisional confidence.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Panattoni</LastName>                    <ForeName>Laura</ForeName>                    <Initials>L</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-5081-5043</Identifier>                    <AffiliationInfo>                        <Affiliation>Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-B232, Seattle, WA, 98109, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lieu</LastName>                    <ForeName>Tracy A</ForeName>                    <Initials>TA</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jayasekera</LastName>                    <ForeName>Jinani</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>O'Neill</LastName>                    <ForeName>Suzanne</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Mandelblatt</LastName>                    <ForeName>Jeanne S</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Lombardi Comprehensive Cancer Center, Washington, DC, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Etzioni</LastName>                    <ForeName>Ruth</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-B232, Seattle, WA, 98109, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Phelps</LastName>                    <ForeName>Charles E</ForeName>                    <Initials>CE</Initials>                    <AffiliationInfo>                        <Affiliation>University of Rochester, Rochester, NY, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ramsey</LastName>                    <ForeName>Scott D</ForeName>                    <Initials>SD</Initials>                    <AffiliationInfo>                        <Affiliation>Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-B232, Seattle, WA, 98109, USA. sramsey@fhcrc.org.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>U01 CA152958</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 CA152958</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R01 CA105274</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>UC2 CA148471</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>ASPO-17-001</GrantID>                    <Agency>American Society of Preventive Oncology</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>UO1 CA183081</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>ACS IRG 92-152-20</GrantID>                    <Agency>American Cancer Society</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>U01 CA183081</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R35CA197289</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>                <Grant>                    <GrantID>R35 CA197289</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 CA105274</GrantID>                    <Agency>National Cancer Institute</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>10</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Breast Cancer Res Treat</MedlineTA>            <NlmUniqueID>8111104</NlmUniqueID>            <ISSNLinking>0167-6806</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Gene expression profile testing</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>23</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30306429</ArticleId>            <ArticleId IdType="doi">10.1007/s10549-018-4988-3</ArticleId>            <ArticleId IdType="pii">10.1007/s10549-018-4988-3</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>